PNC Financial Services Group’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $346K | Buy |
39,523
+493
| +1% | +$3.73K | ﹤0.01% | 2062 |
|
|
2026
Q1 | $299K | Buy |
39,030
+3,930
| +11% | +$26.9K | ﹤0.01% | 2041 |
|
|
2025
Q4 | $69.5K | Sell |
35,100
-10,068
| -22% | -$22.8K | ﹤0.01% | 3026 |
|
|
2025
Q3 | $111K | Buy |
45,168
+31,353
| +227% | +$80.7K | ﹤0.01% | 2737 |
|
|
2025
Q2 | $36.5K | Buy |
13,815
+12,668
| +1,104% | +$34.1K | ﹤0.01% | 3286 |
|
|
2025
Q1 | $3.45K | Buy |
1,147
+1,113
| +3,274% | +$3.37K | ﹤0.01% | 4183 |
|
|
2024
Q4 | $87 | Sell |
34
-2,000
| -98% | -$8.33K | ﹤0.01% | 4715 |
|
|
2024
Q3 | $7.57K | Hold |
2,034
| – | – | ﹤0.01% | 3897 |
|
|
2024
Q2 | $12.9K | Buy |
2,034
+1,000
| +97% | +$6.59K | ﹤0.01% | 3674 |
|
|
2024
Q1 | $5.55K | Sell |
1,034
-1,000
| -49% | -$4.53K | ﹤0.01% | 3929 |
|
|
2023
Q4 | $10.2K | Sell |
2,034
-7,966
| -80% | -$25K | ﹤0.01% | 3722 |
|
|
2023
Q3 | $16.9K | Sell |
10,000
-10,100
| -50% | -$20.3K | ﹤0.01% | 3509 |
|
|
2023
Q2 | $55.9K | Buy |
+20,100
| New | +$56.8K | ﹤0.01% | 2997 |
|
|
2021
Q4 | – | Sell |
-250
| Closed | -$2K | – | 4518 |
|
|
2021
Q3 | $2K | Hold |
250
| – | – | ﹤0.01% | 4113 |
|
|
2021
Q2 | $4K | Hold |
250
| – | – | ﹤0.01% | 3927 |
|
|
2021
Q1 | $6K | Sell |
250
-250
| -50% | -$6.48K | ﹤0.01% | 3773 |
|
|
2020
Q4 | $7K | Sell |
500
-650
| -57% | -$6.25K | ﹤0.01% | 3648 |
|
|
2020
Q3 | $8K | Buy |
1,150
+500
| +77% | +$4.99K | ﹤0.01% | 3578 |
|
|
2020
Q2 | $8K | Buy |
+650
| New | +$3.67K | ﹤0.01% | 3529 |
|
|
2019
Q2 | – | Sell |
-500
| Closed | -$1K | – | 4069 |
|
|
2019
Q1 | $1K | Hold |
500
| – | – | ﹤0.01% | 3952 |
|
|
2018
Q4 | $1K | Hold |
500
| – | – | ﹤0.01% | 3958 |
|
|
2018
Q3 | $2K | Hold |
500
| – | – | ﹤0.01% | 3952 |
|
|
2018
Q2 | $2K | Hold |
500
| – | – | ﹤0.01% | 3984 |
|
|
2018
Q1 | $2K | Hold |
500
| – | – | ﹤0.01% | 4038 |
|
|
2017
Q4 | $2K | Hold |
500
| – | – | ﹤0.01% | 4003 |
|
|
2017
Q3 | $3K | Hold |
500
| – | – | ﹤0.01% | 3947 |
|
|
2017
Q2 | $4K | Hold |
500
| – | – | ﹤0.01% | 3861 |
|
|
2017
Q1 | $2K | Hold |
500
| – | – | ﹤0.01% | 3942 |
|
|
2016
Q4 | $3K | Sell |
500
-1,000
| -67% | -$6.67K | ﹤0.01% | 3775 |
|
|
2016
Q3 | $12K | Hold |
1,500
| – | – | ﹤0.01% | 3421 |
|
|
2016
Q2 | $9K | Hold |
1,500
| – | – | ﹤0.01% | 3601 |
|
|
2016
Q1 | $12K | Hold |
1,500
| – | – | ﹤0.01% | 3496 |
|
|
2015
Q4 | $26K | Sell |
1,500
-75
| -5% | -$1.11K | ﹤0.01% | 3164 |
|
|
2015
Q3 | $18K | Buy |
+1,575
| New | +$34.4K | ﹤0.01% | 3419 |
|
Other funds holding IBRX
SAM
CCA
AH
KA
PNC Financial Services Group's IBRX Position: Q2 2026 in Review
PNC Financial Services Group increased its ImmunityBio (IBRX) stake by 1.3% in Q2 2026, buying an estimated $3.73K and bringing the position to 39,523 shares worth $346K. The position accounts for ﹤0.01% of the portfolio, ranked #2062.
PNC Financial Services Group first reported a position in IBRX in Q3 2015 and has held it in 34 quarters since. 219 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.
- PNC Financial Services Group held 39,523 shares of ImmunityBio worth $346K as of Q2 2026.
- PNC Financial Services Group bought 493 ImmunityBio shares in Q2 2026, an estimated $3.73K.
- ImmunityBio made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #2062 holding.
- PNC Financial Services Group first reported a position in ImmunityBio in Q3 2015 and has held it in 34 quarters since.
- 219 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.
Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.